Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma
出版年份 2019 全文链接
标题
Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma
作者
关键词
-
出版物
LEUKEMIA
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2019-07-24
DOI
10.1038/s41375-019-0517-6
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Combination therapy with carfilzomib, lenalidomide and dexamethasone (KRd) results in an unprecedented purity of the stem cell graft in newly diagnosed patients with myeloma
- (2018) Nishant Tageja et al. BONE MARROW TRANSPLANTATION
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
- (2018) David S. Siegel et al. JOURNAL OF CLINICAL ONCOLOGY
- Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study
- (2018) Philippe Moreau et al. LANCET ONCOLOGY
- Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity
- (2018) Nikoletta Lendvai et al. LEUKEMIA & LYMPHOMA
- Carfilzomib-Associated Cardiovascular Adverse Events
- (2018) Adam J. Waxman et al. JAMA Oncology
- Global Burden of Multiple Myeloma
- (2018) Andrew J. Cowan et al. JAMA Oncology
- Patient-Reported Outcomes (PROs) From the Phase 3 A.R.R.O.W. Study Comparing Once-Weekly versus Twice-Weekly Carfilzomib Dosing in Relapsed and Refractory Multiple Myeloma (RRMM)
- (2018) Philippe Moreau et al. Clinical Lymphoma Myeloma & Leukemia
- Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone
- (2018) Dickran Kazandjian et al. JAMA Oncology
- An overview of the role of carfilzomib in the treatment of multiple myeloma
- (2017) Dimitrios C. Ziogas et al. EXPERT OPINION ON PHARMACOTHERAPY
- Cardiovascular events during carfilzomib therapy for relapsed myeloma: practical management aspects from two case studies
- (2017) Andrzej J. Jakubowiak et al. Hematology
- Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes
- (2017) O. Landgren et al. JOURNAL OF INTERNAL MEDICINE
- Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial
- (2017) Meletios A Dimopoulos et al. LANCET ONCOLOGY
- Management of Carfilzomib-Associated Cardiac Adverse Events
- (2016) Joseph Mikhael Clinical Lymphoma Myeloma & Leukemia
- Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma
- (2016) A. Keith Stewart et al. JOURNAL OF CLINICAL ONCOLOGY
- Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
- (2016) Meletios A Dimopoulos et al. LANCET ONCOLOGY
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
- (2016) Shaji Kumar et al. LANCET ONCOLOGY
- Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD®immunomodulatory drug pomalidomide
- (2015) Deepika S. Das et al. BRITISH JOURNAL OF HAEMATOLOGY
- Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma
- (2015) Joseph R. Mikhael et al. BRITISH JOURNAL OF HAEMATOLOGY
- Minimal residual disease in multiple myeloma: bringing the bench to the bedside
- (2015) Sham Mailankody et al. Nature Reviews Clinical Oncology
- Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
- (2015) A. Keith Stewart et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma
- (2015) Neha Korde et al. JAMA Oncology
- Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study
- (2014) S. Bringhen et al. BLOOD
- Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma
- (2014) P. Sonneveld et al. BLOOD
- Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma
- (2014) D. Dytfeld et al. HAEMATOLOGICA
- Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies
- (2013) D. Siegel et al. HAEMATOLOGICA
- Macrolide antibiotics block autophagy flux and sensitize to bortezomib via endoplasmic reticulum stress-mediated CHOP induction in myeloma cells
- (2013) SHOTA MORIYA et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
- (2012) A. J. Jakubowiak et al. BLOOD
- The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects
- (2012) M A Hurchla et al. LEUKEMIA
- In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells
- (2011) Dharminder Chauhan et al. CLINICAL CANCER RESEARCH
- Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events
- (2011) S. Arastu-Kapur et al. CLINICAL CANCER RESEARCH
- Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues
- (2010) Michel Delforge et al. LANCET ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now